TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01787591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat-Free Milk
Description: Fat-free milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Fat Milk
Description: Low-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full-Fat Milk
Description: Full-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy Milk
Description: Soy milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
Study: NCT02282332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Study: NCT04601272

Intervention type: BEHAVIORAL
Intervention: Decision aid
Description: Healthwise patient decision aids for breast, prostate, colon and lung cancer screening provide information on the pros and cons of cancer screening and guidance in process of selecting a choice.

Intervention type: BEHAVIORAL
Intervention: Decision aid
Description: Healthwise patient decision aids for breast, prostate, colon and lung cancer screening provide information on the pros and cons of cancer screening and guidance in process of selecting a choice.

Intervention type: BEHAVIORAL
Intervention: Decision aid
Description: Healthwise patient decision aids for breast, prostate, colon and lung cancer screening provide information on the pros and cons of cancer screening and guidance in process of selecting a choice.
Study: NCT04248257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PeACE
Description: 3 session peer coaching intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community peer coaching
Description: Peer coaching provided by community organizations that support the HBOC community
Study: NCT03320148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led primary care model for back pain
Description: 1. Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination~2. Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.~3. Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).~4. Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
Study: NCT00172380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel Plus CDDP
Description: docetaxel 36mg/m2 and cisplatin 75mg/m2
Study: NCT02278146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ParaPatch
Description: A device for the treatment of urinary incontinence

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ParaPatch
Description: A device for the treatment of urinary incontinence
Study: NCT03513380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: free access to the exergame PedalTanks during 6 months
Study: NCT03935646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall IR 10mg
Description: At one of the experimental appointments, participants will be administered a stimulant medication. Following a wait period, the participants will complete executive functioning tasks of working memory and sustained attention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT02042131

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Study: NCT04467996

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine balloon tamponade
Description: Intrauterine balloon will be placed in the uterus for postpartum hemorrhage control.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine balloon tamponade
Description: Intrauterine balloon will be placed in the uterus for postpartum hemorrhage control.
Study: NCT04084639

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mycoprotein Ingestion
Description: Ingestion of various doses of mycoprotein compared to placebo control

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mycoprotein Ingestion
Description: Ingestion of various doses of mycoprotein compared to placebo control
Study: NCT02587663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo bilateral breast contrast enhanced MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mammography
Description: Undergo bilateral mammography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mammography
Description: Undergo bilateral mammography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mammography
Description: Undergo bilateral mammography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo breast conserving surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo breast conserving surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo breast conserving surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Undergo bilateral whole-breast ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonography
Description: Undergo targeted breast ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Undergo targeted breast ultrasound
Study: NCT02209636

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Table identical to lanthanum carbonate but with no active ingredient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Intravenous administration during measurement of flow mediated dilation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ascorbic Acid
Description: Intravenous administration during measurement of flow mediated dilation.
Study: NCT03869827

Intervention type: OTHER
Intervention: necrotizing enterocolitis
Description: Collection of necrotizing enterocolitis diagnosis, as well as its severity, are based on the classification of Belle modified in 3 stages: 1) Suspected, 2) Proven, 3) Advanced

Intervention type: OTHER
Intervention: necrotizing enterocolitis
Description: Collection of necrotizing enterocolitis diagnosis, as well as its severity, are based on the classification of Belle modified in 3 stages: 1) Suspected, 2) Proven, 3) Advanced
Study: NCT02042131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Crisis Response Plan (S-CRP)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Crisis Response Plan (E-CRP)
Study: NCT02587663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Undergo targeted breast ultrasound

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Contrast agent used in MRI
Study: NCT00603499

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium chloride
Description: Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the control group received inert placebo once per day during 4 months
Study: NCT02584608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTIMMUNE
Study: NCT03587545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic nasal spray
Description: Total daily nasal administration of 2\*10\^8 CFU of probiotic bacteria delivered via 2 servings.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic nasal spray
Description: Total daily nasal administration of 2\*10\^8 CFU of probiotic bacteria delivered via 2 servings.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic nasal spray
Description: Total daily nasal administration of 2\*10\^8 CFU of probiotic bacteria delivered via 2 servings.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic nasal spray
Description: Total daily nasal administration of 2\*10\^8 CFU of probiotic bacteria delivered via 2 servings.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Two servings of nasal administration of placebo nasal spray (not containing probiotic bacteria)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Two servings of nasal administration of placebo nasal spray (not containing probiotic bacteria)
Study: NCT01580371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-581
Description: CKD-581 qd for Day 1, 8 and 15 every 28days/Cycle
Study: NCT02942576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VKA-Based Regimen
Description: Dosed at International Normalised Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in Canada, Italy, Poland, Hungary, Czech Republic, United Kingdom (UK), Taiwan and Korea.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VKA-Based Regimen
Description: Dosed at INR levels. Standard of Care treatment in Germany, Belgium, and the Netherlands.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VKA-Based Regimen
Description: Dosed at INR levels. Standard of Care treatment in France.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VKA-Based Regimen
Description: Dosed at INR levels. Standard of Care treatment in Spain.
Study: NCT04473482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Michigan Alcohol Improvement Network-Alcohol Reduction and Treatment tool
Description: The intervention corrects misconceptions about alcohol use, liver disease, and alcohol treatment and matches patients to their top three choices of treatment while providing them with brief explanations of each treatment option.
Study: NCT03007069

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mineralized plasmatic matrix (MPM).
Description: By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM, for 10 minutes , Which will result if sticky bone graft consistency after mixing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autogenous bone graft (gold standard).
Description: Exposed implant threads are to be covered with autogenous bone and collagen membrane.
Study: NCT02943902

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV10 ) 1+1, 6 weeks
Description: PCV10 1+1, 6 weeks \& 9 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV10 ) 1+1, 14 weeks
Description: PCV10 1+1, 14 weeks \& 9 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine (PCV10 ) 2+1
Description: PCV10 2+1, 6\&14 weeks \& 9 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV13 ) 1+1, 6 weeks
Description: PCV13 1+1, 6 weeks \& 9 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV13 ) 1+1, 14 weeks
Description: PCV13 1+1, 14 weeks \& 9 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine (PCV13 ) 2+1
Description: PCV13 2+1, 6\&14 weeks \& 9 months
Study: NCT01124266

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard of care colonoscopy
Description: Single inspection by endoscopist during colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard of care colonoscopy
Description: Dual inspection by both endoscopist and nurse during colonoscopy
Study: NCT03632720

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine
Description: Pharmaceutical form: solution for injection; route of administration: intramuscular, 0.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine
Description: Pharmaceutical form: solution for injection; route of administration: intramuscular, 0.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal group B vaccine
Description: Pharmaceutical form: suspension for injection; route of administration: deep intramuscular, 0.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal group B vaccine
Description: Pharmaceutical form: suspension for injection; route of administration: deep intramuscular, 0.5 mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal group B vaccine
Description: Pharmaceutical form: suspension for injection; route of administration: deep intramuscular, 0.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine
Description: Pharmaceutical form: powder and suspension for suspension injection; route of administration: deep intramuscular, 0.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine
Description: Pharmaceutical form: powder and suspension for suspension injection; route of administration: deep intramuscular, 0.5 mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine
Description: Pharmaceutical form: powder and suspension for suspension injection; route of administration: deep intramuscular, 0.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human rotavirus RIX4414 strain vaccine
Description: Pharmaceutical form: oral suspension; route of administration: oral, 1.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human rotavirus RIX4414 strain vaccine
Description: Pharmaceutical form: oral suspension; route of administration: oral, 1.5 mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human rotavirus RIX4414 strain vaccine
Description: Pharmaceutical form: oral suspension; route of administration: oral, 1.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent polysaccharide conjugate vaccine
Description: Pharmaceutical form: suspension for injection; route of administration: intramuscular, 0.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent polysaccharide conjugate vaccine
Description: Pharmaceutical form: suspension for injection; route of administration: intramuscular, 0.5 mL
Study: NCT02209636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: Drug that is administered under the tongue that relaxes blood vessels. To be administered during measurement of flow mediated dilation.
Study: NCT03632720

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 13-valent polysaccharide conjugate vaccine
Description: Pharmaceutical form: suspension for injection; route of administration: intramuscular, 0.5 mL
Study: NCT01528852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 4%
Description: 4% liquid solution used for cord cleaning once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 4%
Description: Chlorhexidine 4% liquid solution used for cord cleaning once daily for 10 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control cord cleaning solution
Description: Mild soapy solution used to clean cord once daily for 10 days
Study: NCT01290354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Unlabelled, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C] lapatinib
Description: Radiolabelled, administered intravenously
Study: NCT04902144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Medical data collected

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Receive coaching
Study: NCT05237635

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: descriptive case-scenarios
Description: Each case-scenario will include: (1) a GRADE Summary of Finding (SoF) table providing information about the Population, Intervention, Comparator, Outcome (PICO), the relative and absolute anticipated effects of the intervention, and the certainty in the evidence; (2) a Health Outcome Descriptor describing key attributes of the outcome under consideration including symptoms, time horizon, testing and treatment, and consequences; a measure of the impact on health of the outcome (also known as 'value' of the outcome or 'health utility' in health economics).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: descriptive case-scenarios
Description: Each case-scenario will include: (1) a GRADE Summary of Finding (SoF) table providing information about the Population, Intervention, Comparator, Outcome (PICO), the relative and absolute anticipated effects of the intervention, and the certainty in the evidence; (2) a Health Outcome Descriptor describing key attributes of the outcome under consideration including symptoms, time horizon, testing and treatment, and consequences; a measure of the impact on health of the outcome (also known as 'value' of the outcome or 'health utility' in health economics).
Study: NCT00216736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Single dose oral dexamethasone 8mg at time of ED discharge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single dose oral placebo at ED discharge
Study: NCT02282722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational informed consent for chemotherapy
Description: Investigational informed consent materials consist of regimen-specific multimedia tools: a video plus a booklet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual, standard-of-care informed consent for chemotherapy
Description: The enrolling site's institutional standard-of-care informed consent materials.
Study: NCT02081105

Intervention type: OTHER
Group type: OTHER
Intervention: PEEP of 5 or 15 cm H2O
Description: PEEP of 5 or 15 cm H2O set at the respirator and applied to the patient for 10 minutes. Then, measurements are made at each PEEP in the following order: arterial blood gas, CXR, pressure-volume curve.

Intervention type: OTHER
Group type: OTHER
Intervention: PEEP of 5 or 15 cm H2O
Description: PEEP of 5 or 15 cm H2O set at the respirator and applied to the patient for 10 minutes. Then, measurements are made at each PEEP in the following order: arterial blood gas, CXR, pressure-volume curve.
Study: NCT02658487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vosaroxin
Description: Given IV
Study: NCT02575651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib either at 10,20,40,80,120mg ....., capsule oral.
Study: NCT04516460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interventional arm: endoscopic resection plus PuraStat®
Description: Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to prevent bleeding after endoscopic resection of colorectal neoplastic lesions
Study: NCT04692558

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HYALURONIC ACID
Description: Hyaluronic acid will be applied on denuded root surface after reflection of isolated gingival recession.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronally advanved flap with connective tissue harvesting
Description: Coronally advanced flap surgery with connective tissue harvesting from palate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronally advanved flap with connective tissue harvesting
Description: Coronally advanced flap surgery with connective tissue harvesting from palate
Study: NCT02541227

Intervention type: DRUG
Intervention: Cerebrolysin
Description: Cerebrolysin dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
Study: NCT00721435

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Tomosynthesis and ultrasound imaging
Description: 3D tomosynthesis \& ultrasound imaging for scanning masses or healthy breast tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Tomosynthesis and ultrasound imaging
Description: 3D tomosynthesis \& ultrasound imaging for scanning masses or healthy breast tissue
Study: NCT03822754

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV-bOPV-bOPV vaccination schedule
Description: Single intramuscular injection of the experimental sIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by Sinovac Vaccine Technology Co., Ltd. The poliovirus (Live) vaccine type I \& type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: wIPV-bOPV-bOPV vaccination schedule
Description: Single intramuscular injection of the control wIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively.The control wild strain inactivated poliovirus vaccine (wIPV) was manufactured by SANOFI PASTEUR S.A. The poliovirus (Live) vaccine type I \& type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.